Efficacy of prolonged-release fampridine

Background

MOBILE and ENHANCE were similarly designed randomized trials of walking-impaired adults with relapsing-remitting or progressive multiple sclerosis (MS) who received placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 weeks. Both studies showed sustained and clinically meaningful improvement in broad measures of walking and balance over 24 weeks of PR-fampridine treatment.

Objective

To evaluate the functional benefits and safety of PR-fampridine

Methods

Data from the intention-to-treat (ITT) populations of MOBILE and ENHANCE studies were pooled in a

Findings

In the ITT population (

Conclusion

The pooled analysis of MOBILE and ENHANCE confirms previous evidence that treatment with PR-fampridine results in clinically meaningful improvements in walking, mobility and balance, self-reported physical impact of MS, and quality of life and is effective across a broad range of PwMS.

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Raymond Hupperts has received compensation for consulting, advisory boards and research grants and as a speaker for lectures from Biogen, and Merck. Claudio Gasperini has received compensation for consulting from Bayer HealthCare and Biogen and as a speaker for lectures from Biogen, Bayer HealthCare, Genzyme, Merck Serono, Novartis and Teva. Jan Lycke has received travel support and/or lecture honoraria from Biogen, Novartis, Merck, Alexion, Roche and Sanofi Genzyme; has served on scientific advisory boards for Biogen, Novartis, Merck, Roche, BSM and Sanofi Genzyme; serves on the editorial board of the Acta Neurologica Scandinavica; and has received unconditional research grants from Biogen and Novartis. Tjalf Ziemssen has received compensation for advisory boards, trial steering committees and data and safety monitoring committees, and speaker fees and project support, from Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, and Teva. Peter Feys has received advisory board fees for Biogen and Novartis, speaker fees from Excemed, and is an editorial board member for Multiple Sclerosis Journal and Neurorehabilitation and Neural Repair. Jeremy Hobart has received consulting/advisor fees, honoraria, and research support from Acorda, Biogen, Genzyme, Global Blood Therapeutics, Merck Serono, Novartis, Tigercat, and Vanita. Shan Xiao was an employee of and held stock/stock options in Biogen at the time the research was conducted. Carlos Acosta and Thijs Koster are employees of and hold stock/stock options in Biogen.